Watch ANAB. Know when insiders buy.
One email the day a filing lands. Free.
ANAB
ANAPTYSBIO, INC
48.10
+0.16 +0.33%
USD · close Oct 22
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
42
WATCH · insiders 38, shorts 46
Insiders, 90 days
−$249K
net selling · 0 buys, 1 sell
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $1.4BP/E 8.4DIV YIELD —FCF YIELD —REV TTM $237.6M +92.9%NET INCOME $195.7MNET CASH —52W 22.06 – 69.81NEXT EARNINGS Nov 3 EST.SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30derived | $27.5M | +23.5% | — | $67M | $183.9M | — | 5.34 | −$26.6M | — | — | Sep 21 |
| Q1 2026 · Mar 31 | $25.6M | −8.0% | — | −$34.6M | −$52.9M | — | -1.84 | −$25.9M | $17K | −$25.9M | May 12 |
| Q4 2025 · Dec 31derived | $108.2M | +151.1% | — | $245.9M | $49.6M | — | 1.72 | $98M | $1K | $98M | Sep 21 |
| Q3 2025 · Sep 30 | $76.3M | +154.3% | — | $34.7M | $15.1M | — | 0.52 | −$27.4M | $12K | −$27.4M | Nov 4 |
| Q2 2025 · Jun 30 | $22.3M | +102.9% | — | −$26.2M | −$38.6M | — | -1.34 | −$40.2M | $39K | −$40.3M | Sep 21 |
| Q1 2025 · Mar 31 | $27.8M | +286.8% | — | −$27.5M | −$39.3M | — | -1.28 | −$10.7M | $35K | −$10.7M | May 12 |
| Q4 2024 · Dec 31derived | $43.1M | +378.8% | — | $171.4M | −$21.8M | — | -0.46 | −$66.7M | $263K | −$66.9M | Sep 21 |
| Q3 2024 · Sep 30 | $30M | +804.7% | — | −$22.8M | −$32.9M | — | -1.14 | −$10.1M | $35K | −$10.1M | Nov 4 |
| Q2 2024 · Jun 30 | $11M | — | — | −$40.3M | −$46.7M | — | -1.71 | −$21.3M | $33K | −$21.4M | Nov 4 |
| Q1 2024 · Mar 31 | $7.2M | — | — | −$42.2M | −$43.9M | — | -1.64 | −$37.3M | $27K | −$37.3M | Nov 4 |
| Q4 2023 · Dec 31derived | $9M | — | — | −$42.1M | −$42.2M | — | -1.59 | −$34.3M | $280K | −$34.6M | Apr 28 |
| Q3 2023 · Sep 30 | $3.3M | — | — | −$37.7M | −$37.3M | — | -1.41 | −$36.5M | $162K | −$36.6M | Nov 5 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $234.6M | — | $226.9M | −$13.2M | -5.6% | -0.44 | $19.7M | $87K | $19.6M | $68.6M | — |
| FY2024 · to Dec 31 | $91.3M | — | $66.2M | −$145.2M | -159.1% | -4.92 | −$135.3M | $358K | −$135.7M | $456K | — |
| FY2023 · to Dec 31 | $17.2M | — | −$164.4M | −$163.6M | -953.7% | -6.08 | −$120.8M | $807K | −$121.6M | $50M | — |
| FY2022 · to Dec 31 | $10.3M | — | −$115.2M | −$128.7M | -1251.3% | -4.57 | −$73.6M | $358K | −$74M | $0 | — |
| FY2021 · to Dec 31 | $63.2M | — | −$56.8M | −$57.8M | -91.5% | -2.11 | −$45.9M | $1.4M | −$47.3M | $0 | — |
| FY2020 · to Dec 31 | $75M | — | −$23.9M | −$19.9M | -26.6% | -0.73 | −$14.2M | $569K | −$14.7M | — | — |
Every number comes from ANAPTYSBIO, INC's own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.